Tag: active surveillance

New research asks if healthy lifestyle choices—like diet, supplements, and exercise—can slow the growth of low-risk prostate cancer during active surveillance. While results remain inconclusive, promising signs exist, and minimally invasive focal therapy is emerging as an alternative option. keep reading

Not all cancer-fighting tools come in a prescription bottle. Recent findings reveal that regular exercise can suppress tumor activity, ease cancer-related anxiety, and tip treatment outcomes in men’s favor—even before prostate cancer treatment starts. Could lacing up your sneakers have a surprising impact on prostate cancer’s course? keep reading

Can a cancer diagnosis bring a sense of relief? For men with prostate cancer caught at Grade Group 1, emerging research and expert protocols suggest that aggressive treatments can often be avoided. Active surveillance, targeted focal therapies, and more precise diagnostic tools are helping many choose paths that spare quality of life. keep reading

Research indicates that regular mpMRI scans and PSA density checks might allow some prostate cancer patients on active surveillance to delay confirmatory biopsy at one year. While the evidence is promising, experts say more study is needed before changing established protocols. keep reading

Recent long-term data reveal that active surveillance can offer high prostate cancer-specific survival when paired with advanced monitoring tools like multiparametric MRI and biomarkers. Experts emphasize the importance of a proactive, technology-driven approach to achieve the best treatment-free survival. keep reading

What happens when a doctor’s advice doesn’t match a patient’s priorities? For men facing low-risk prostate cancer, finding agreement on management—whether monitoring, aggressive treatment, or focal therapy—can shape both outcomes and satisfaction. New insights highlight how shared decision-making brings patient goals into clearer focus. keep reading

Did you know over 95% of prostate cancers share the same name—adenocarcinoma? This common cell type is usually slow-growing, but not always. Understanding how it develops, why PSA levels matter, and what early detection can reveal is key to knowing your best treatment options. keep reading

How do you stop overtreatment before it happens? New data shows fewer men are undergoing surgery for low-risk prostate cancer, while focal therapies are emerging as a way to control disease without sacrificing quality of life. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

Gleason 3+3 prostate cancer is often considered low-risk—so low that some experts say it shouldn’t even be called cancer at all. But could a new label change how patients view their diagnosis and choices? The answer may reshape the future of prostate cancer care. keep reading